Tag: MTC HEA PHA

HLS Therapeutics Announces Q2 2025 Financial Results

Adjusted EBITDA grew 21% in Q2 and 29% year-to-date Cash from operations grew 83% in Q2 and 147% year-to-dateMade principal repayments on the Company's...

Jazz Pharmaceuticals to Report Second Quarter Financial Results on August 5, 2025

DUBLIN, July 22, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2025 second quarter financial results on...

Elysium Therapeutics’ Investor Webcast Highlights “Fentanyl Rebound” as Key Challenge in Reducing Opioid Overdose Hospitalizations and Deaths

Elysium's Synthetic Opioid Overdose Prevention and Reversal (SOOPR™) technology designed specifically to combat oral fentanyl overdose LYONS, Colo., June 11, 2025 /PRNewswire/ -- Elysium Therapeutics,...

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

Phone

This field is for validation purposes and should be left unchanged.

HomeTagsMTC HEA PHA

Director/PDMR Shareholding

Aptean Appoints Yama Habibzai as Chief Marketing Officer

Taboola Announces Inclusion in Russell 3000® and 2000® Index

Tag: MTC HEA PHA

HLS Therapeutics Announces Q2 2025 Financial Results

Jazz Pharmaceuticals to Report Second Quarter Financial Results on August 5, 2025

Elysium Therapeutics’ Investor Webcast Highlights “Fentanyl Rebound” as Key Challenge in Reducing Opioid Overdose Hospitalizations and Deaths

Newsletter Signup

Explore

Press Releases

News & Opinion

Living

Others

Follow us